TXG

10x Genomics, Inc.

Fundamental data last updated:June 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Healthcare Information Services

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/06/2026

Business Summary

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

 


VALUATION

P/E

-158.50

Market Cap ($M USD)

$3.55B

Forward P/E

-365.09

PEG

-6.45

PRICE TO SALES

5.56

PRICE TO BOOK

4.41

EV / EBITDA

-534.16

5-Year Average P/E

Free Cash Flow Yield

3.44%

DCF Value

$-13.03

Graham Number

N/A

Price to FCF

29.08

EV to FCF

25.74

Earnings Yield

-0.63%

FCF Yield

3.44%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.18

Next Year EPS Growth Estimate

-$0.08

Next Year Revenue Growth Estimate

$90.47B

Return on Equity (ROE)

-2.86%

FREE CASH FLOW

Operating Margin

-6.06%

Debt-to-Equity

0.20

Piotroski F-Score

4

Altman Z-Score

8.41

Return on Invested Capital (ROIC)

-4.29%

Current Ratio

5.90

Quick Ratio

5.42

Net Debt to EBITDA

69.46

Interest Coverage

-6450.50

Gross Profit margin

69.60%

FCF PER SHARE

$0.95

REVENUE PER SHARE

$4.98

Gainseekers Quantitative Analysis

Summary

TXG’s valuation paints a complex picture. The market has priced it significantly above its DCF value, suggesting a disconnect between current expectations and intrinsic worth. With a Forward P/E of -135 and a negative Earnings Yield, profitability remains elusive. Yet, the Altman Z-score of 7.71 indicates financial stability, hinting at a low risk of bankruptcy. This juxtaposition of high valuation and solid financial health creates a perplexing investment thesis.

AI Exposure / Tech Reliance

Operating within the Medical - Healthcare Information Services industry, TXG is well-positioned to leverage AI advancements. The sector's inherent need for data-driven solutions aligns with TXG's capabilities, potentially enhancing its service offerings. This adaptability could be a key driver in maintaining relevance amidst technological shifts.

The Bull Case

For the discerning GARP investor, TXG offers intriguing prospects. Despite its negative ROIC of -4.29%, the company boasts a robust FCF Yield of 4.39%, indicating efficient cash generation relative to its market cap. A Piotroski F-Score of 4 suggests moderate financial health, while a Gross Profit Margin of nearly 70% underscores strong pricing power. These metrics collectively suggest a company capable of capitalizing on its operational efficiencies.

The Bear Case

However, the bear case cannot be ignored. TXG's Price/Book ratio of 3.40 and Price/Sales of 4.36 reflect a potentially overvalued stock, especially given its negative EPS and operating margin. The stock's proximity to its 52-week high, with a mere 22.43% distance, raises concerns of technical overextension. These factors, combined with a negative EV to EBITDA, highlight significant structural risks.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$22.43

Institutional Ownership %

1-Year Beta

2.05

Insider Buying % (6 Mo)

Distance to 52-Week High

0.64%

Distance to 52-Week Low

68.04%

EARNINGS SURPRISE %

65.52%

50-DAY SMA

$22.19

200-DAY SMA

$17.81

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.